Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 8;15(3):e0009253.
doi: 10.1371/journal.pntd.0009253. eCollection 2021 Mar.

Control of cystic echinococcosis in the Middle Atlas, Morocco: Field evaluation of the EG95 vaccine in sheep and cesticide treatment in dogs

Affiliations

Control of cystic echinococcosis in the Middle Atlas, Morocco: Field evaluation of the EG95 vaccine in sheep and cesticide treatment in dogs

Fatimaezzahra Amarir et al. PLoS Negl Trop Dis. .

Abstract

Background: Cystic echinococcosis (CE) is an important cause of human morbidity and mortality worldwide, particularly in Morocco and other North African countries.

Methodology/principal findings: We investigated the potential of three strategies to reduce Echinococcus granulosus transmission: (1) 4-monthly treatment of dogs with praziquantel, (2) vaccination of sheep with the EG95 vaccine and (3) a combination of both measures. These measures were implemented during four consecutive years in different areas of the Middle Atlas Mountains in Morocco. The outcome of the interventions was assessed through hydatid cyst (viable and non-viable) counts in liver and lungs using necropsy or in vivo ultrasound examination of the liver. A total of 402 lambs were recruited for annual vaccination with the EG95 anti-E. granulosus vaccine and 395 similar lambs were selected as non-vaccinated controls. At approximately four years of age the relative risk (estimated as odds ratio) for vaccinated sheep to have viable hydatid cysts compared with non-vaccinated controls was 3% (9.37% of the vaccinated sheep were found infected while 72.82% of the controls were infected; p = 0.002). The number of viable cysts in vaccinated animals was reduced by approximately 97% (mean counts were 0.28 and 9.18 respectively; p<0.001). An average of 595 owned dogs received 4-monthly treatment during the 44 months trial, corresponding to 91% of the owned dog population. Approximately, 5% of them were examined for E. granulosus adult worms by arecoline purge or eggs in feces (confirmed by PCR). The proportion of infected dogs significantly decreased after treatment (12% versus 35%; p<0.001). Post-treatment incidence of re-infestation corresponded to a monthly risk of 4% (95% CI: 3-6%). Treatment of owned dogs on a 4-monthly basis did not reduce the level of transmission of E. granulosus to sheep, nor did it enhance the level of control generated by vaccination of sheep with EG95, possibly because of unowned dogs and wild canids were not treated.

Conclusions/significance: These data suggest that vaccination of sheep with EG95 has the potential to reduce the level of CE in Morocco and in other parts of the world with similar transmission dynamics. Under the epidemiological circumstances existing in the trial area, 4-monthly treatment of owned dogs with praziquantel was insufficient to have a major impact of E. granulosus transmission to sheep.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Location of the three study sites in the Middle Atlas, Morocco (https://fr.wikipedia.org/wiki/G%C3%A9ographie_du_Maroc).
Fig 2
Fig 2
Effect of vaccination and dog therapy on prevalence and abundance of live cysts in sheep exposed for 4 years to a natural E. granulosus challenge (data extracted from Tables 6 and 8) A: Prevalence of infection in vaccinated and control sheep, B: Prevalence of infection in control sheep with or without treatment of dogs, C: Mean number of live cysts per sheep in vaccinated and control sheep, D: Mean number of live cysts per control sheep with or without treatment of dogs.

References

    1. Tahiri S, Naoui H, Iken M, Azelmat S, Bouchrik M, Lmimouni BE. Seroprevalence of cystic echinococcosis in the provinces of Ifrane and El Hajeb in Morocco. Med Mal Infect. 2020. 10.1016/j.medmal.2019.12.007 - DOI - PubMed
    1. El Berbri I, Petavy AF, Umhang G, Bouslikhane M, Fassi Fihri O, Boué F, et al.. Epidemiological Investigations on cystic echinococcosis in North-West (Sidi Kacem Province) Morocco: Infection in Ruminants. Adv Epidemiol. 2015: 1–9. 10.1155/2015/104025 - DOI
    1. Sadjjadi SM. Present situation of echinococcosis in the Middle East and Arabic North Africa. Parasitol Int. 2006;55: 197–202. 10.1016/j.parint.2005.11.030 - DOI - PubMed
    1. Alvarez Rojas (a) CA , Romig T, Lightowlers MW. Echinococcus granulosus sensu lato genotypes infecting humans—review of current knowledge. Int J Parasitol. 2014;44: 9–18. 10.1016/j.ijpara.2013.08.008 - DOI - PubMed
    1. Alvarez Rojas CA, Gauci CG, Lightowlers MW. Antigenic differences between the EG95-related proteins from Echinococcus granulosus G1 and G6 genotypes: Implications for vaccination. Parasite Immunol. 2013;35: 99–102. 10.1111/pim.12009 - DOI - PubMed

Publication types